Antares Pharma, Inc. (ATRS) Comparison with companies in other sectors?

Antares Pharma, Inc. has a share price of N/A. You can analyze Antares Pharma, Inc. (ATRS) competitors across different market sectors through stock heatmaps.

What are ATRS's NET and operating margins?

Antares Pharma, Inc. (ATRS) operating margin is around 0.34, and net profit margin is approximately 0.25 as of the latest reports.

In what way does ATRS's earnings per share (EPS) trend reflect its financial momentum?

Antares Pharma, Inc. (ATRS) EPS is 0.37 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Antares Pharma, Inc. is 14.95, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Antares Pharma, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Antares Pharma, Inc. like P/E which is 20.55, P/B which is 5.41, and PEG which is 0.21. Compare them with sector averages to evaluate if the stock is priced fairly.

Antares Pharma, Inc.

ATRS•NASDAQ

Healthcare

Medical - Instruments & Supplies

$5.59

$0.010(0.18%)

Fundamental Analysis of Antares Pharma, Inc. (ATRS)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.37

P/E Ratio

14.95

ROE

0.31%

Net Margin

0.25%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$0.00

Shares OutstandingTotal number of shares issued

Book Value/ShareNet worth per share

$1.03

Revenue/ShareAnnual revenue per share

$1.08

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.374

Net MarginNet income as percentage of revenue

25.16%

Operating MarginOperating income as percentage of revenue

33.85%

ROEReturn on shareholders' equity

31.40%

ROAReturn on total assets

17.98%

ROCEReturn on capital employed

31.36%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.18

Cash/ShareCash and equivalents per share

$0.39

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ATRSFinancial Ratios Analysis details for ATRS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ATRSSector Benchmarking details for ATRS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Antares Pharma, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Antares Pharma, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Antares Pharma, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Antares Pharma, Inc.

For Antares Pharma, Inc., essential financial indicators include EPS 0.37, PE 14.95, and ROE 0.31. These key ratios reveal insights into Antares Pharma, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Antares Pharma, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Antares Pharma, Inc.

Metrics like Net Margin 25.16% and ROA 17.98% shed light on how well Antares Pharma, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Antares Pharma, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Antares Pharma, Inc.

Using ratios such as P/B Ratio 5.41 and PEG Ratio 0.21, investors can assess whether Antares Pharma, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Antares Pharma, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Antares Pharma, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.14 and Cash Flow $0.18, provide a snapshot of Antares Pharma, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Antares Pharma, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Antares Pharma, Inc.

Investing in Antares Pharma, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Antares Pharma, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;